Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck comments on progress of Vioxx payments

Merck comments on progress of Vioxx payments

5th March 2008

Pharmaceutical company Merck (MSD) has provided an update regarding payments for consumers who claim they were adversely affected by the use of Vioxx (rofecoxib).

The arthritis drug was originally approved but later linked to an increase risk of heart attack and stroke. MSD is in the process of determining submissions from claimants who were affected.

It said more than 44,000 of the 47,000 individuals who had registered injuries have now collected the required information MSD needs to decide whether they qualify for payment.

These relate to myocardial infection (MI) and ischemic stroke (IS) claims filed against Merck.

“We are very pleased with the large number of enrolments we are seeing,” said Ted Mayer of defense counsel Hughes Hubbard & Reed.

“There is a considerable amount of documentation that has to be reviewed before the definitive determination.”

So far, the qualifying scheme is only available to US consumers who ingested Vioxx. They must provide proof of MI or IS, receipt of no less than 30 Vioxx pills and a “proximity gate” to support Vioxx ingestion within 14 days prior to the injury.

The New Jersey-based company officially withdrew Vioxx in September 2004 after a clinical trial discovered the increased risk of cardiovascular events after 18 months of taking the drug.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.